Foundayo™ and decreased appetite

Where appetite appears in the official documents

Foundayo™ contains orforglipron, a GLP-1 receptor agonist taken as one tablet a day, with or without food ^[1]. Its label does not describe orforglipron as a peptide; the trial publications call it a small-molecule, non-peptide agonist ^[9]. The pharmacology section explains that GLP-1 is a natural regulator of appetite and calorie intake, that its receptors sit in brain areas that control appetite, and that in animal studies orforglipron reached and activated neurons in those areas ^[1].

The label’s Table 1 lists reactions seen in at least 5% of treated people and more often than on placebo, and it does not include a decreased-appetite row ^[1]. Appetite comes up instead as part of how the medicine works. The Medication Guide’s list of common side effects does not name it either ^[2].

What the trial registries counted

Eli Lilly and Company posted full adverse-event tables for the orforglipron trials on ClinicalTrials.gov. The two 72-week weight trials, ATTAIN-1 and ATTAIN-2, are the label’s Trial 1 and Trial 2; the label shows their 6, 12 and 36 mg trial doses as the equivalent Foundayo™ strengths of 5.5, 9 and 17.2 mg ^[1][5][6]. The ACHIEVE trials were in type 2 diabetes, a use the US label does not cover, and used the trial doses as given.

Reading those numbers

• The label describes lower food intake as a general effect of the tablet, yet only a minority of trial participants had decreased appetite recorded as an adverse event. The registry counts an event when a participant or investigator reported it, so the figures describe appetite loss that was noticed and noted, not the everyday drop in hunger.
• The pattern with dose is not neat. In ATTAIN-2 the rate climbed with each dose, but in ATTAIN-1 the middle dose had the highest figure ^[5][6].
• People with type 2 diabetes reported it more often in these tables. The trials were not designed to compare the two groups, so this is an observation, not a proven difference.
• Against oral semaglutide in ACHIEVE-3, the figures were close, and the trial was open label, which means participants knew which tablet they took ^[8].
• Registry tables give no timing, severity or duration for this event. The ATTAIN-1 publication reports that adverse events of any kind led 5.3% to 10.3% of people on orforglipron to stop treatment ^[9], and the label adds that most such stops were for stomach effects ^[1].

Why the tablet blunts hunger

Two effects in the label fit together. The first is central: GLP-1 receptors in the brain’s appetite centres, which orforglipron activated in animal work ^[1]. The second is in the gut: Foundayo™ slows stomach emptying, and the label notes that this delay is largest after the first dose and shrinks over time ^[1]. A fuller stomach for longer is a plausible reason meals feel smaller early on, but the label does not measure how much each effect contributes to appetite.

The label also reports that weight lost on Foundayo™ included more fat mass than lean mass ^[1]. It does not report vitamin levels or nutrient intake, so whether eating less leads to shortfalls in a given person is something only testing and a clinician can answer.

Other reasons appetite can fall

MedlinePlus notes that almost any illness can dull appetite and that sadness, depression or grief often do ^[10]. It lists other causes worth keeping in mind, so a new loss of appetite is not automatically blamed on the tablet:

• An underactive thyroid, long-term liver or kidney disease, heart failure or chronic lung disease.
• Infections such as hepatitis, and the first months of pregnancy.
• Other medicines, including some antibiotics, chemotherapy, codeine and morphine.
• Low mood, grief and an eating disorder, which need their own care.

What the guidance suggests

The Foundayo™ label pairs the tablet with a reduced-calorie diet and more physical activity; in the trials everyone received diet and activity counselling from the first dose ^[1]. It does not set a calorie floor or a meal plan, so the target is a conversation with your prescriber or a dietitian.

For anyone whose appetite has dropped, MedlinePlus suggests keeping a record of everything you eat and drink for at least a day, which gives your clinician something concrete to judge ^[10]. For appetite loss caused by a medicine, it advises asking your provider about the dose or the medicine rather than stopping it yourself ^[10]. The Medication Guide asks you to drink fluids to lower the chance of dehydration when stomach side effects strike ^[2].

Because the label allows the tablet with or without food, a skipped or small breakfast does not change how Foundayo™ is taken ^[1]. If you also use insulin or a sulfonylurea, the label’s warning matters more: in Trial 2, low blood sugar below 54 mg/dL was reported by 7% of people on orforglipron with a sulfonylurea, compared with 0.5% of those not taking one ^[1].

Points that apply to this tablet

Foundayo™ is started at 0.8 mg and stepped up no sooner than every 30 days, with 17.2 mg as the highest dose ^[1]. Noting how hungry you feel before and after each step gives your prescriber a timeline to set against the dose changes.

If seven or more doses in a row are missed, the label says to restart at a lower dose to reduce stomach side effects ^[1]. A return of appetite during a long gap, and a dip after restarting, are worth recording in the same way.

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.